Aestus Non Confidential Intro 062410

1,553 views
1,476 views

Published on

Updated introduction to Aestus Therapeutics including news on Phase 2 trials of a first-in-class novel pain medication, and investment opportunities.

Published in: Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,553
On SlideShare
0
From Embeds
0
Number of Embeds
24
Actions
Shares
0
Downloads
22
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Aestus Non Confidential Intro 062410

  1. 1. Investment Opportunity Non-Confidential Status Update June, 2010
  2. 2. Aestus Therapeutics Inc Founded in 2005, Aestus is a translational medicine company focused on the accelerated development of first-in-class therapeutics for nervous system disorders The Aestus key proprietary element is our unique systems biology engine to discover novel targets for the diseases of interest Aestus validates these targets using compounds developed for other indications Aestus opportunistically in-licenses active compounds from this target validation for Phase 2 clinical studies 2
  3. 3. Management Tage Honore, President & CEO: Previously, Vice President at Novo Nordisk, Novartis, and Purdue Pharma. Brought more than 35 new drug concepts to early clinical studies in multiple disease conditions, of which three were launched. Managed budgets for a total of $1B, achieving record pipeline productivity in several companies. Ph D. in Medicinal Chemistry and Doctor of Science in Neurobiology from the Royal Danish School of Pharmacy in Denmark. Business training from European Management Centre and Harvard Business School. 3
  4. 4. Management, cont F. Aaron Dubberley, Director of Intellectual Property: Previously, McAulay Nissen Goldberg Kiel & Hand (now the New York IP group for Reed Smith), Hoffmann-La Roche, Aventis and senior U.S. patent attorney at Organon International. Thirteen years of pharma IP experience, including all aspects of patent acquisition, freedom-to-operate, IP due diligence and licensing. MS. in Biochemistry and Molecular Biology from University of California, Davis, and JD. from Rutgers. 4
  5. 5. Management, cont Dan Lavery, Director, Research and Genomics: Previously, Director, Molecular Biology, Chromocell Corporation, research and management positions at Glaxo SmithKline and Purdue Pharma Twenty years of experience in differential gene expression, target ID & validation Managed $36 million multi-year research collaboration on molecular biology of taste BA, Johns Hopkins University and PhD., Mt. Sinai Medical School/NYU. Post-doctoral researcher and Lecturer, University of Geneva, Switzerland. 5
  6. 6. Status Update Our most advanced product, ATx08-001, enters clinical phase 2 proof of efficacy studies this quarter for treatment of post- herpetic neuralgia (PHN) as a first-in-class novel pain therapeutic. These studies are funded by a non-dilutive SBIR grant totaling $2.6 million from NIH. 6
  7. 7. Investment Proposition Aestus is seeking capital to expand our portfolio of products for neuropathic pain in addition to the current phase 2 pain trial of ATx08-001. Proceeds will be used to progress two additional products in neuropathic pain, ATx09-002 and ATx03-005, which act at different targets than ATx08-001, in proof-of-concept phase 2 trials on PHN. Proceeds will also fund pre-clinical and clinical studies on treatments for schizophrenia and ALS, over the next 2-5 years. Revenue will be created by sub-license to or collaboration with pharma in late stage clinical studies, NDA and product launch. 7 Near-term value milestones identified.
  8. 8. The Aestus Pipeline Pre-clinical Patent filing, Clinical Proof- Project Data analysis Compound ID validation in-licensing of-efficacy Neuropathic ATx08-001, ATx09-002, ATx03-005 pain ALS (Lou Gehrig’s 4 compounds disease) Schizophrenia 30 compounds Epilepsy Other disease areas ~ 1 year ~ 1 year ~ 1.5 – 2 years 8
  9. 9. Clinical trial compounds All three compounds showed robust performance in universally accepted pre-clinical models of neuropathic pain (Chung, Bennett); excellent safety profile and no serious adverse events in phase 1 and 2 clinical studies for original indications. ATx08-001: • MW: 468.4 • PPAR gamma agonist • Aestus: Initiating phase 2 trials in PHN this quarter ATx09-002: • MW: 481.36 • Glycogen phosphorylase inhibitor • Aestus: in-license term sheet negotiated ATx03-005: • MW 500.54 • Fructose 1,6-bisphosphatase inhibitor • Aestus: in-license term sheet negotiated 9
  10. 10. Investment and Value Creation $10M investment: Clinical Phase 2 proof of efficacy of two products (ATx09-002, ATx03-005) for post-herpetic neuralgia • Third product, ATx08-001, now beginning Phase 2 clinical trials for PHN, financed by non-dilutive SBIR grant Value creation steps: Out-license of product(s) after successful Phase 2a pain trial (2-3 years)‫‏‬ Partnering for full development of product after successful Phase 2 trials (3+ years)‫‏‬ Acquisition, trade sale or IPO of Aestus (5+ years)‫‏‬ 10
  11. 11. Five Year Budget Aestus Therapeutics Inc Five–year Financial Plan (all values in $) 2010 2011 2012 2013 2014 Revenue SBIR phase 2 grant 1,500,000 1,500,000 0 0 0 Milestone payments to Aestus for ATx08-001 0 0 30,000,000 0 25,000,000 Milestone payments to Aestus for ATx09-002 0 0 30,000,000 0 25,000,000 Milestone payments to Aestus for ATx-Schizo 0 0 0 30,000,000 0 Total Revenue 1,500,000 1,500,000 50,000,000 30,000,000 50,000,000 Product cost In-license payment for ATx08-001 1,000,000 0 0 0 0 Milestone payment for ATx08-001 0 0 5,000,000 0 5,000,000 In-license payment for ATx09-002 1,000,000 0 0 0 0 Milestone payment for ATx09-002 0 0 15,000,000 12,500,000 In-license payment for ATx-Schizo 0 1,000,000 0 0 Milestone payment for ATx-Schizo 5,000,000 0 Total product cost 2,000,000 1,000,000 20,000,000 5,000,000 17,500,000 Operating expenses Clinical development costs 3,000,000 4,500,000 1,500,000 0 0 Research to expand portfolio, salaries/ benefits, infrastructure 1,400,000 1,400,000 1,400,000 1,400,000 1,400,000 Total operating expenses 4,400,000 5,900,000 2,900,000 1,400,000 1,400,000 EBIT -4,900,000 -5,400,000 37,100,000 23,600,000 31,100,000 Projections based on terms of comparable pharma license agreements, and assuming successful clinical development and partnering 11 of three Aestus products. = milestone payment for entry into Phase 3 trials = milestone payment for NDA filing
  12. 12. Investment summary Reduced risk in PHN Phase 2 clinical trials Exclusive WW license from COM owner in place Managed by a high-calibre, highly experienced team of industry executives Extensive use of out-sourcing to keep burn rate low Potential sub-licensees already identified and awaiting data An attractive, balanced portfolio 12
  13. 13. ATx In-license and IP Status Products ATx09-002 ATx08-001 ATx03-005 In-license status Agreed Signed Negotiating License scope Exclusive Exclusive Exclusive Field NP Human therapy NP-DN Territory Worldwide Worldwide Worldwide Patent life Composition of matter patent (issued) 2024* 2016* 2019* Use patent (application) 2027* 2030* 2027* * = Plus data exclusivity and any available patent term extension NP = Neuropathic pain DN = Diabetic neuropathy 13
  14. 14. Aestus Core Technology
  15. 15. The Aestus Engine 1. Aestus-proprietary disease-relevant genomics databases 2. Aestus-proprietary data QC, • Also leverage public genomics databases (GEO, EBI) statistical meta-analysis across multiple datasets c a b 4. Mapping of gene clusters to biological pathways: 3. Aestus-proprietary a) Known pathways – validate analysis biologically-informed cluster b) Novel pathways – may be of value for discovery analysis c) Aestus-proprietary novel association of disease to 15 well-studied pathways
  16. 16. The Aestus Engine 4. Mapping of gene clusters to biological pathways: c) Aestus-proprietary novel association of disease to well-studied pathways 5. Identify Phase 1+ compounds 6. Validate novel pathways using Phase 1+ compounds in acting at these pathways, pre-clinical disease models (e.g., pain models above) developed for other indications - Aestus-proprietary use patents (e.g., Aestus patent application US2010/0076037) - In-license for Phase 2 clinical development 16
  17. 17. Aestus Discovery & Development Model Identify novel disease targets through the proprietary Aestus engine for systems biology data-mining Identify de-risked compounds (Phase 2-ready) developed for other indications, acting at our targets Validate pathways with these compounds in pre-clinical animal models Patent active compounds for novel utility (Aestus IP) Obtain exclusive worldwide license from composition of matter owner Show proof of efficacy in clinical phase 2 trial Co-develop/out-license with pharma partner for later-stage 17 development
  18. 18. Aestus Platform vs. Compound Reprofiling 18
  19. 19. Aestus Platform vs. Compound Reprofiling Aestus has succeeded where compound reprofiling failed: Using Aestus platform, several novel pain targets were identified and validated with compounds acting at these targets Aestus approached the composition of matter owner of one compound to negotiate in-licensing agreement for clinical development as pain product Owner had already engaged a major compound reprofiler to identify other appropriate indications Six months later and after failure to identify novel indications by reprofiler, owner contacted Aestus to negotiate our proposal 19
  20. 20. Third Party Validation Pain Research collaboration – (Public traded pharmaceutical company, (name withheld))‫‏‬ Small Business Innovation Research Grants – Phase I and Phase II (National Institute of Neurological Disorders and Stroke (NINDS))‫‏‬ – $2.6 million non-dilutive funding for Phase 2 clinical trial of Aestus pain product ATx08-001, initiated this year Edison Innovation Research and Development Grant – (New Jersey Commission on Science and Technology (NJCST))‫‏‬ – $500K non-dilutive funding License partners – (Four publicly traded Pharmaceutical companies, 20 (names withheld))‫‏‬
  21. 21. Intellectual Property Three provisional and three non-provisional PCT applications filed, including: – WO2008/057930A2 – WO2008/057933A2 – WO2008/063842A2 – US 2010/0076037 21
  22. 22. Infrastructure Located in Commercialization Centre for Innovative Technologies, New Brunswick, NJ • Cost effective, state supported, located on US Highway 1 5 full time employees on payroll: • Tage Honore, President & CEO • Aaron Dubberley, Director Intellectual Properties • Daniel Lavery, Director Research & Genomics • Meredith Prysak, Project management • Kathy Kerrigan, Administrative Assistant 3 further employees to be employed in the future: • VP Commercial • Director Informatics • VP Clinical All others are advisors and consultants 22
  23. 23. Supplemental information Selected data from validation of ATx08-001 and ATx09-002 in animal models of neuropathic pain
  24. 24. Clinically-validated Neuropathic Pain Models 24 Confidential
  25. 25. ATx08-001 in chronic pain model ATx08-001 reverses pain behavior (cold allodynia) in rats in the Bennett chronic constriction model of neuropathic pain. Reversal of pain behavior by ATx08-001 was equal to or greater than equivalent doses of the positive control pain medication, carbamazepine. Error bars, SEM; * = p < 0.05 compared to vehicle. 25
  26. 26. ATx09-002 in chronic pain model (I) ATx09-002 reverses pain behavior (cold allodynia) in rats in the Bennett chronic constriction model in a dose-dependent manner. Reversal of pain behavior by ATx09- 002 at 100 mg/kg was equal to that of 100 mg/kg carbamazepine, the positive control. Error bars = SEM; * = p < 0.05 versus vehicle. 26
  27. 27. ATx09-002 in chronic pain model (II) ATx09-002 reverses pain behavior (mechanical allodynia) in rats in the Chung spinal nerve ligation model of neuropathic pain. Reversal of pain behavior by ATx09-002 (30 mg/kg) was greater than that by greater doses of the positive control pain medication, carbamazepine (100 mg/kg; * = p < 0.05, ATx09-002 vs. carbamazepine; error bars = SEM). 27

×